Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Spinraza to Hit Japan Market on August 30
August 28, 2017
- Astellas to Integrate Regenerative Medicine Research into US Unit
August 25, 2017
- Otsuka, Mylan Ink TB Deal for 29 Developing Countries
August 25, 2017
- Bayer Instruction Existed in Patient Info Acquisition, Sales Rep Tells Govt Panel
August 25, 2017
- Japan NDA Filed for Lymphoma Med Obinutuzumab: Chugai/Nippon Shinyaku
August 24, 2017
- CureApp to Begin Clinical Trial of Japan’s First “Treatment App” in October
August 24, 2017
- 1st Patient Dosed in PIII for Gilteritinib as Post-HCT AML Maintenance Therapy: Astellas
August 23, 2017
- Takeda Files Japan NDA for Entyvio
August 23, 2017
- External Activities of Takeda Unit Axcelead to Go Full Throttle This Autumn: President
August 23, 2017
- Japan’s “Advanced Drug” Market Put at 1.4 Trillion Yen in 2016: Fuji Keizai
August 22, 2017
- PII Study Launched for Sanwa Kagaku/Ube’s Pruritus Drug
August 22, 2017
- Mitsubishi Tanabe Begins Japan PII/III for Regeneron Pain Med
August 18, 2017
- Opdivo Gets 4th Indication in Taiwan for Head and Neck Cancer
August 17, 2017
- Harvoni Top-Selling Drug in Japan in FY2016, Opdivo Jumps but Drop Expected for FY2017: Jiho Tally
August 17, 2017
- Me Pharma to Roll Out Mevalotin, Gaster Generics in February
August 16, 2017
- Arbitration against Chugai Begins over Add’l Actemra Royalty
August 16, 2017
- 5 Diabetes Drugs in Top 10 List in June GP Recollection Ranking: Anterio
August 15, 2017
- Ethical Drug Sales Up 0.4% in June: Crecon
August 14, 2017
- Wholesalers See Lower Price Settlement Rates as Customers’ Business Flounders
August 9, 2017
- Hisamitsu to Form China Subsidiary, Enhance Sales via Direct Route
August 9, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…